HADHB and coronary artery disorder: Trimetazidine improved myocardial glucose utilization through inhibition of long-chain 3-ketoacyl CoA thiolase activity, which results in a reduction in fatty acid oxidation and a stimulation of glucose oxidation in ischemic heart disease.